跳转至内容
Merck
CN

103R-9

CD3 (MRQ-39) Rabbit Monoclonal Antibody

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

rabbit

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-39, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

pkg of 0.1 mL concentrate (103r-94)
pkg of 0.5 mL concentrate (103R-95)
pkg of 1.0 mL concentrate (103R-96)
pkg of 1.0 mL predilute (103R-97)
pkg of 7.0 mL predilute (103R-98)

manufacturer/tradename

Cell Marque®

IVD

for in vitro diagnostic use

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

isotype

IgG1

control

tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

membranous

Quality Level

Gene Information

human ... CD3E(916)

Analysis Note


IVD

IVD

IVD

RUO

General description

Anti-CD3 has been considered the best all around T-cell marker. This antibody reacts with an antigen present in early thymocytes. The positive staining of this marker may represent a sign of early commitment to the T-Cell lineage.

Other Notes

CD3 Positive Control Slides, Product No. 103S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

SM Denning, et al.
Leucocyte Typing III, 144-147 (1987)
Kennosuke Karube et al.
The American journal of surgical pathology, 27(10), 1366-1374 (2003-09-26)
We studied the morphologic, immunohistochemical, and clinical characteristics of 158 cases of lymphoblastic lymphoma. Based on immunophenotyping and cell lineage, cases were classified into B-cell type (CD20,CD19 or CD79a+, n = 53), T-cell type (surface CD3+, n = 84), and
Ulla Axdorph et al.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 110(5), 379-390 (2002-06-22)
Morphologically, T-cell-rich B-cell lymphoma (TCRB-NHL) may be indistinguishable from Hodgkin's disease (HD). Immunophenotyping may be helpful in the separation of these entities. TCRB-NHL is occasionally misdiagnosed and treated as HD. However, information is limited regarding clinical characteristics and outcome of
Ahmet Dogan et al.
The American journal of surgical pathology, 27(7), 903-911 (2003-06-27)
Occasionally, primary large B-cell lymphomas (LBLs) arising in the spleen present with a micronodular pattern involving the splenic white pulp but sparing the red pulp. Histologically, the nodules contain scattered large B cells in a background of numerous T cells
E A Clark et al.
Immunology today, 10(7), 225-228 (1989-07-01)
During 1987, striking advances were made in defining the receptors and ligands for cell-to-cell adhesion interactions involving leukocytes. In 1988, two major leukocyte differentiation antigens, CD10 (cALLA) and CD45 (LCA, T200), were shown to be enzymes while two other markers

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持